Our mission is to discover drugs for high unmet medical needs that will improve quality of life for patients with Rare Diseases.
We stand out by our ability to deliver high value products with relatively little cost in a short period of time, due to our model we reduce the risk of drug development.
SOM Biotech has a strong pipeline of products focused on CNS at preclinical and clinical stages.
NEWS & PRESS RELEASES
SOMCT02 Huntington’s disease trial recruits 100% of patient target
On March 8, 2019, the SOMCT02 clinical trial successfully closed recruitment, marking 100% fulfillment of […]
SOM Biotech closes a financing round of 7M Euros
SOM Biotech has just closed a financing round of 7 million euros led by a […]
Rare Disease Day 2019
Today, February 28th, is Rare Disease Day, and SOM Biotech is one with Eurordis in […]
Drug Repurposing for Rare Diseases Conference 2019
Findacure‘s Drug Repurposing for Rare Diseases Conference is returning for its sixth consecutive year on […]
SOM Biotech renews collaboration with Biotechnology Business Institute
With the opening of the Postgraduate programs of Biotechnology Business Institute for the school year 2019, SOM […]
SOM Biotech at Biotech Showcase/J.P. Morgan 2019
Starting the year seizing business opportunities, SOM Biotech attended the Biotech Showcase/J.P. Morgan Conference held […]
Executing strategies for maximizing firm value
2018 WAS ANOTHER IMPORTANT YEAR FOR SOM BIOTECH with new rounds of investments, a clinical […]
Season’s greetings from SOM
Each year, the SOM Biotech team celebrates Christmas by dining out and doing some fun activities […]
Early Stage Value Creation Panel Discussion
Farmantra, a Barcelona-based corporate finance advisory for life sciences companies specializing in early stage valuations, […]
SOMCT02 Huntington’s disease trial recruits 50% of patient target
On November 2, 2018, the SOMCT02 clinical trial successfully recruited its 15th patient, marking 50% […]